Ipratropium/Salbutamol Cipla

Salbutamol, the active ingredient in Ipratropium/Salbutamol Cipla, is a bronchodilator presented as a fixed‑dose combination inhalation product for inhalation use. Together with ipratropium bromide monohydrate, it provides rapid relief of airway constriction in asthma, chronic obstructive pulmonary disease (COPD) and acute bronchospasm for both adult and pediatric patients as directed by a healthcare professional.

GNH USA supplies Ipratropium/Salbutamol Cipla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and procurement teams worldwide.

Ipratropium/Salbutamol is a bronchodilator combination indicated for obstructive airway diseases. - Asthma: provides rapid bronchodilation to relieve acute symptoms and improve airflow. - Chronic obstructive pulmonary disease (COPD): enhances lung function and reduces exacerbations when used as maintenance therapy. - Acute bronchospasm: delivers fast‑acting relief during sudden airway constriction episodes.

Ipratropium/Salbutamol may cause adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Tremor: mild shaking of the hands or limbs. - Palpitations: sensation of rapid or irregular heartbeat. - Throat irritation: discomfort or soreness in the throat. - Cough: transient increase in coughing after inhalation.

Serious or Rare Side Effects: - Paradoxical bronchospasm: worsening airway constriction after use. - Angioedema: swelling of face, lips, tongue or throat. - Severe allergic reaction: rash, itching, swelling, dizziness or difficulty breathing.

When prescribing Ipratropium/Salbutamol, clinicians should consider the following precautions. - Assess cardiac history: monitor patients with known heart disease for tachycardia or arrhythmias. - Evaluate respiratory status: use cautiously in patients with severe airway obstruction or recent respiratory infection. - Review concomitant β‑agonists: avoid excessive dosing when combined with other β2‑agonists. - Monitor for paradoxical bronchospasm: discontinue if symptoms worsen after inhalation. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk, as safety data are limited. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Ipratropium/Salbutamol can interact with other medicines, requiring attention to the following.

Major Interactions (Avoid): - Non‑selective β‑blockers: may diminish bronchodilator effect and precipitate bronchospasm. - Monoamine oxidase inhibitors (MAOIs): increase risk of cardiovascular side effects when combined with salbutamol. - Anticholinergic overload: concurrent use with other anticholinergics may enhance dry mouth and urinary retention.

Moderate Interactions (Monitor Closely): - Diuretics and digitalis: may increase risk of hypokalemia and arrhythmias with salbutamol. - Theophylline: additive bronchodilator effect may require dose adjustment. - Inhaled corticosteroids: monitor for increased risk of oral thrush when used together.